Bessemer Group’s CG Oncology CGON Stock Holding History

Bessemer Group’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-35	Closed	-$1K	–	2487
2024 Q3	$1K	Buy	+35	New	+$1.23K	﹤0.01%	2363

Other funds holding CGON

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bessemer Group's CGON Position: Q4 2024 in Review

Bessemer Group sold out of CG Oncology (CGON) in Q4 2024, closing a stake of 35 shares — an estimated $1K sold.

Bessemer Group first reported a position in CGON in Q3 2024 and held it in 1 quarter. The position peaked at $1K in Q3 2024. 140 funds tracked by Wall St. Rank hold CGON as of Q4 2024.

Bessemer Group reported no remaining CG Oncology position as of Q4 2024 after selling out during the quarter.
Bessemer Group sold 35 CG Oncology shares in Q4 2024, an estimated $1K.
Bessemer Group first reported a position in CG Oncology in Q3 2024 and held it in 1 quarter.
Bessemer Group's CG Oncology position peaked at $1K in Q3 2024.
140 funds tracked by Wall St. Rank held CG Oncology as of Q4 2024.

Based on Bessemer Group's 13F filing for Q4 2024, filed 13 Feb 2025.